Genentech will no longer be producing Nutropin AQ® (somatropin) NuSpin® formulations due to a combination of business considerations and the availability of alternative growth hormone options for patients.
Nutropin AQ NuSpin is a recombinant human growth hormone indicated for the treatment of children with growth failure due to growth hormone deficiency (GHD), idiopathic short stature, Turner syndrome, and chronic kidney disease up to the time of renal transplantation. It is also approved for the treatment of adults with childhood-onset or adult-onset GHD.
In the press release, the Company noted that all formulations of Nutropin AQ NuSpin will be discontinued on December 31, 2024. The discontinuation of these products is unrelated to any product quality, safety, or efficacy issues.
Health care providers and patients with issues related to this transition can call the Nutropin support line at 1-866-Nutropin (866-688-7674).
References:
Genentech provides update on Nutropin AQ® (somatropin) NuSpin® formulations in the United States. News release. Genentech. March 15, 2024. Accessed March 20, 2024. https://www.gene.com/media/statements/ps_031524.
-
Share on Facebook
-
Share on Twitter
-
Share on LinkedIn
-
Share by Email
-
Print
